These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model. Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the clinical use of PET/CT with Ribeiro AMB; Lima ENP; Zequi SC Urol Oncol; 2021 Jan; 39(1):73.e9-73.e18. PubMed ID: 32861620 [TBL] [Abstract][Full Text] [Related]
6. FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging. Masters SC; Hofling AA; Gorovets A; Marzella L Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):27-28. PubMed ID: 33857629 [No Abstract] [Full Text] [Related]
7. The Agony and Ecstasy of Prostate Cancer PSMA PET. Gomella LG Can J Urol; 2021 Apr; 28(2):10574-10575. PubMed ID: 33872551 [No Abstract] [Full Text] [Related]
8. Incidental finding of COVID-19 infection after [ Stasiak CES; Cardoso FR; de Almeida SA; Rosado-de-Castro PH Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):653-654. PubMed ID: 32710224 [No Abstract] [Full Text] [Related]
9. Findings in 1,123 Men with Preoperative Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140 [TBL] [Abstract][Full Text] [Related]
10. PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. Lopci E; Lughezzani G; Castello A; Colombo P; Casale P; Saita A; Buffi NM; Guazzoni G; Chiti A; Lazzeri M Clin Transl Oncol; 2021 Jan; 23(1):172-178. PubMed ID: 32447644 [TBL] [Abstract][Full Text] [Related]
14. Comparative study of the most commonly-used radiopharmaceuticals for PSMA prostate PET/CT imaging. Pasini E; Panagiotidis E; Zoglopitou LA; Kalathas T; Makridou A; Chatzipavlidou V Hell J Nucl Med; 2022; 25(1):83-87. PubMed ID: 35388805 [TBL] [Abstract][Full Text] [Related]
15. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer. BJU Int; 2021 Aug; 128(2):127-130. PubMed ID: 34318983 [No Abstract] [Full Text] [Related]
16. De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515 [TBL] [Abstract][Full Text] [Related]
17. Reduced Acquisition Time per Bed Position for PET/MRI Using Duan H; Baratto L; Hatami N; Liang T; Levin CS; Khalighi MM; Iagaru A AJR Am J Roentgenol; 2022 Feb; 218(2):333-340. PubMed ID: 34406051 [No Abstract] [Full Text] [Related]
18. PSMA Avidity in the Heterotropic Ossification-An Incidental Finding on PSMA PET/CT. Jain TK; Vohra M; Sharma BS; Dhal S; Sharma LM Clin Nucl Med; 2024 Mar; 49(3):e118-e119. PubMed ID: 38271263 [TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and high risk prostate cancer. El Hajj A; Yacoub B; Mansour M; Khauli R; Bulbul M; Nassif S; Haidar MB Medicine (Baltimore); 2019 Nov; 98(44):e17491. PubMed ID: 31689752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]